sunitinib pharmagen 50 mg
pharmagen cz s.r.o., Česká republika - sunitinib - 44 - cytostatica
sunitinib pharmagen 25 mg
pharmagen cz s.r.o., Česká republika - sunitinib - 44 - cytostatica
sunitinib pharmagen 12,5 mg
pharmagen cz s.r.o., Česká republika - sunitinib - 44 - cytostatica
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib sandoz 50 mg tvrdé kapsuly
sandoz pharmaceuticals d.d., slovinsko - sunitinib - 44 - cytostatica
sunitinib sandoz 25 mg tvrdé kapsuly
sandoz pharmaceuticals d.d., slovinsko - sunitinib - 44 - cytostatica
sunitinib sandoz 12,5 mg tvrdé kapsuly
sandoz pharmaceuticals d.d., slovinsko - sunitinib - 44 - cytostatica
sunitinib g.l. pharma 50 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - sunitinib - 44 - cytostatica
sunitinib g.l. pharma 25 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - sunitinib - 44 - cytostatica
sunitinib g.l. pharma 12,5 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - sunitinib - 44 - cytostatica